What's New


License Agreement Has Been Entered into with RheinCell Therapeutics

We have executed a non-exclusive license agreement with RheinCell Therapeutics GmbH (Germany) for conducting a GMP-grade iPS cell bank consisting of various cord blood derived so-called HLA-homozygous cells under the patents on iPS cell technologies licensed to us by Kyoto University.

RheinCell Therapeutics GmbH

Back to top